What's on this Page
What is Tagraxofusp
Tagraxofusp-erzs is a CD123-directed cytotoxin that is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm in adult and pediatric patients 2 years of age and older.
Capillary leak syndrome has been reported with tagraxofusp therapy
Brand Name
ELZONRIS
Indications
- blastic plasmacytoid dendritic cell neoplasm
Side Effects
- anemia
- anorexia
- antibody formation
- anxiety
- back pain
- bradycardia
- capillary leak syndrome
- chills
- confusion
- constipation
- cough
- diarrhea
- dizziness
- dyspnea
- edema
- elevated hepatic enzymes
- epistaxis
- fatigue
- fever
- headache
- hematuria
- hyperbilirubinemia
- hyperglycemia
- hyperkalemia
- hypermagnesemia
- hypernatremia
- hypertension
- hypoalbuminemia
- hypocalcemia
- hypoglycemia
- hypokalemia
- hypomagnesemia
- hyponatremia
- hypophosphatemia
- hypotension
- insomnia
- nausea
- neutropenia
- peripheral edema
- petechiae
- pruritus
- rash
- sinus tachycardia
- stomatitis
- thrombocytopenia
- vomiting
- weight gain
- wheezing
Monitoring Parameters
- blood pressure
- heart rate
- LFTs
- pregnancy testing
- serum albumin
- serum creatinine
- weight
Contraindications
- breast-feeding
- capillary leak syndrome
- contraception requirements
- geriatric
- hepatic disease
- pregnancy
- pregnancy testing
- renal impairment
- reproductive risk
- serious rash
Interactions
- Palifermin
- Penicillamine
- Tuberculin Purified Protein Derivative, PPD
